Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus

INTRODUCTION: Epratuzumab, a humanized anti-CD22 monoclonal antibody, is under investigation as a therapeutic antibody in non-Hodgkin's lymphoma and systemic lupus erythematosus (SLE), but its mechanism of action on B-cells remains elusive. Treatment of SLE patients with epratuzumab leads to a...

Descripción completa

Detalles Bibliográficos
Autores principales: Daridon, Capucine, Blassfeld, Daniela, Reiter, Karin, Mei, Henrik E, Giesecke, Claudia, Goldenberg, David M, Hansen, Arne, Hostmann, Arwed, Frölich, Daniela, Dörner, Thomas
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3046510/
https://www.ncbi.nlm.nih.gov/pubmed/21050432
http://dx.doi.org/10.1186/ar3179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3046510/
https://www.ncbi.nlm.nih.gov/pubmed/21050432
http://dx.doi.org/10.1186/ar3179

Ejemplares similares